Twist Bioscience (NASDAQ:TWST) Price Target Lowered to $33.00 at JPMorgan Chase & Co.

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its price target cut by equities researchers at JPMorgan Chase & Co. from $40.00 to $33.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an "underweight" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 7.07% from the company's current price.

A number of other equities analysts have also recently issued reports on TWST. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Stock Down 5.5 %

Shares of NASDAQ TWST traded down $1.79 during mid-day trading on Tuesday, hitting $30.82. 1,158,651 shares of the stock traded hands, compared to its average volume of 968,895. The stock has a fifty day moving average price of $38.63 and a 200-day moving average price of $43.66. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. Twist Bioscience has a 52 week low of $30.72 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Research analysts anticipate that Twist Bioscience will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the transaction, the chief operating officer now owns 265,460 shares in the company, valued at $10,615,745.40. The trade was a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,991 shares of company stock worth $742,654 in the last three months. 3.01% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc increased its position in Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience during the third quarter worth $34,000. Finally, Banque Transatlantique SA acquired a new stake in Twist Bioscience in the fourth quarter worth about $43,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.